Automate Your Wheel Strategy on PROK
With Tiblio's Option Bot, you can configure your own wheel strategy including PROK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PROK
- Rev/Share 0.004
- Book/Share 2.5966
- PB 0.9801
- Debt/Equity 0.0104
- CurrentRatio 11.4797
- ROIC -0.5308
- MktCap 760948388.0
- FreeCF/Share -1.3208
- PFCF -4.4069
- PE -4.5907
- Debt/Assets 0.0094
- DivYield 0
- ROE 0.1101
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PROK | BofA Securities | Neutral | Underperform | -- | $1 | June 30, 2025 |
| Initiation | PROK | JP Morgan | -- | Neutral | -- | -- | Sept. 30, 2024 |
| Initiation | PROK | Guggenheim | -- | Buy | -- | $6 | Sept. 10, 2024 |
News
ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
ProKidney Corp. (NASDAQ:PROK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Bruce Culleton - CEO & Director James Coulston - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good morning, everyone. Welcome to the Morgan Stanley Global Healthcare Research Conference.
Read More
ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
ProKidney Corp. (NASDAQ:PROK ) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Bruce Culleton - CEO & Director Ethan Holdaway Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome, everyone, to the next session of the Citi's Biopharma back-to-school Summit. So we are literally back to school, checking up on all the companies.
Read More
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September:
Read More
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Best Momentum Stocks to Buy for July 17th
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
Read More
New Strong Buy Stocks for July 17th
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.
Read More
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
Read More
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
Published: July 09, 2025 by: Yahoo Finance
Sentiment: Positive
Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.
Read More
Why Is Penny Stock ProKidney Trading Higher On Tuesday?
Published: July 08, 2025 by: Benzinga
Sentiment: Positive
ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.
Read More
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and …
Read More
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
About ProKidney Corp. (PROK)
- IPO Date 2021-06-30
- Website https://www.prokidney.com
- Industry Biotechnology
- CEO Bruce Culleton
- Employees 204